Loading...
•
Sep 30, 2023
SpringWorks Therapeutics Q3 2023 Earnings Report
Reported third quarter financial results and provided recent business highlights.
Key Takeaways
SpringWorks Therapeutics reported a net loss of $79.4 million, or $1.27 per share, for the third quarter of 2023. The company's cash, cash equivalents and marketable securities were $422.4 million as of September 30, 2023. They are on track to report topline data from the Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN in the fourth quarter of 2023.
PDUFA target action date for nirogacestat NDA in adults with desmoid tumors remains set for November 27, 2023
On track to report topline data from the Phase 2b ReNeu trial of mirdametinib in patients with NF1-PN in the fourth quarter of 2023
Presented additional Phase 3 DeFi data at CTOS demonstrating statistically significant and clinically meaningful improvements in functional status in desmoid tumor patients treated with nirogacestat
First patient dosed in Regeneron-sponsored Phase 1b study arm evaluating nirogacestat in combination with linvoseltamab in patients with multiple myeloma
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...